X

Trial Profile

Study of VNRX-5133 in combination with a clinically validated broad spectrum beta-lactam for bacterial infections.

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 22 Mar 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cefepime/taniborbactam (Primary) ; Beta-lactams
Indications Bacterial infections
Focus Registrational; Therapeutic Use
Sponsors VenatoRx Pharmaceuticals

Most Recent Events

19 Mar 2018 According to the VenatoRx Pharmaceuticals media release, company will start this pivotal registration trial in mid 2018
08 Jan 2018 According to VenatoRx Pharmaceuticals pipeline, phase of this trial is phase II/III. (www.venatorx.com/pipeline/)
08 Jan 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com